Literature DB >> 8114668

Localization of mRNA for three distinct alpha 1-adrenergic receptor subtypes in human tissues: implications for human alpha-adrenergic physiology.

D T Price1, R J Lefkowitz, M G Caron, D Berkowitz, D A Schwinn.   

Abstract

alpha 1-Adrenergic receptors (alpha 1ARs) are virtually ubiquitous in human tissues and mediate important physiological functions as diverse as smooth muscle contraction, glycogenolysis, and myocardial inotropy. At least three alpha 1AR subtypes (alpha 1A/D, alpha 1B, and alpha 1C) have been described using molecular and pharmacological techniques. The identification of species heterogeneity (rat versus rabbit) in alpha 1AR subtype distribution has made it imperative to determine the distribution of alpha 1AR subtypes in human tissues. Accordingly, RNA extracted from human tissues was analyzed using RNase protection assays to determine alpha 1AR subtype expression. Of the cloned alpha 1ARs, alpha 1CAR mRNA predominates in many human tissues (heart, liver, cerebellum, and cerebral cortex), in contrast to its restricted distribution in both rats and rabbits. alpha (1B)AR mRNA is present in highest concentrations in human spleen, kidney, and fetal brain. alpha 1A/DAR mRNA is present in highest concentrations in human aorta and cerebral cortex. Hence, alpha 1AR subtype mRNA distribution is tissue selective and differs from that reported for rats and rabbits. These results have potentially significant implications for understanding human adrenergic physiology and are important for the rational development of alpha 1AR subtype-selective drugs.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8114668

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  33 in total

Review 1.  Regulation of cardiac sarcolemmal Na+/H+ exchanger activity: potential pathophysiological significance of endogenous mediators and oxidant stress.

Authors:  M Avkiran; A K Snabaitis
Journal:  J Thromb Thrombolysis       Date:  1999-07       Impact factor: 2.300

2.  Neuron specific alpha-adrenergic receptor expression in human cerebellum: implications for emerging cerebellar roles in neurologic disease.

Authors:  U B Schambra; G B Mackensen; M Stafford-Smith; D E Haines; D A Schwinn
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

3.  Isoform-specific dynamic translocation of PKC by α1-adrenoceptor stimulation in live cells.

Authors:  Jin O-Uchi; Jaime Sorenson; Bong Sook Jhun; Jyotsna Mishra; Stephen Hurst; Kaleef Williams; Shey-Shing Sheu; Coeli M B Lopes
Journal:  Biochem Biophys Res Commun       Date:  2015-08-12       Impact factor: 3.575

Review 4.  Alterations in adrenergic receptor signaling in heart failure.

Authors:  S Lamba; W T Abraham
Journal:  Heart Fail Rev       Date:  2000-03       Impact factor: 4.214

Review 5.  Alpha1-adrenoceptor subtypes and lower urinary tract symptoms.

Authors:  Debra A Schwinn; Claus G Roehrborn
Journal:  Int J Urol       Date:  2008-03       Impact factor: 3.369

Review 6.  Subtypes of alpha1-adrenoceptors in BPH: future prospects for personalized medicine.

Authors:  Yoshiyuki Kojima; Shoichi Sasaki; Yutaro Hayashi; Gozoh Tsujimoto; Kenjiro Kohri
Journal:  Nat Clin Pract Urol       Date:  2009-01

7.  Efficacy of alpha-Adrenergic Receptor Blockers in the Treatment of Male Lower Urinary Tract Symptoms.

Authors:  Claus G Roehrborn
Journal:  Rev Urol       Date:  2009

8.  Adrenergic regulation of the rapid component of delayed rectifier K+ currents in guinea pig cardiomyocytes.

Authors:  Sen Wang; Xiao-Yan Min; Si-Si Pang; Jin Qian; Di Xu; Yan Guo
Journal:  J Thorac Dis       Date:  2014-12       Impact factor: 2.895

Review 9.  Classification of alpha 1-adrenoceptor subtypes.

Authors:  M C Michel; B Kenny; D A Schwinn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-07       Impact factor: 3.000

Review 10.  Silodosin in the treatment of benign prostatic hyperplasia.

Authors:  Maxime Rossi; Thierry Roumeguère
Journal:  Drug Des Devel Ther       Date:  2010-10-27       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.